Trulicity Cost in Vermont 2026: Pricing, Insurance, and Savings Options

What Does Trulicity Actually Cost at Vermont Pharmacies?

The retail cash price for brand-name Trulicity in Vermont sits at approximately $931 per month in 2026, matching Eli Lilly's national list price. This figure represents the wholesale acquisition cost passed through to uninsured or out-of-network patients at most Vermont retail chains and independent pharmacies.

That $931 figure assumes no insurance, no discount card, and no manufacturer assistance. Most Vermont residents will pay substantially less. A 2024 IQVIA analysis of GLP-1 receptor agonist utilization found that fewer than 15% of patients filling branded GLP-1 prescriptions paid full retail price, with the majority accessing some form of third-party coverage or manufacturer support [1]. The gap between list price and actual out-of-pocket cost matters here. Patients filling Trulicity at CVS, Walgreens, Kinney Drugs, or local Vermont independents should always ask the pharmacy to run their insurance first and then apply any available discount card before accepting the cash price.

Trulicity is dispensed as a single-dose pen in cartons of four (one month's supply at once-weekly dosing). The pen comes prefilled and does not require reconstitution or refrigeration after first use (up to 14 days at room temperature), which simplifies storage for Vermont patients managing cold-weather shipping concerns during winter months [2].

Vermont Medicaid Coverage for Trulicity

Vermont Medicaid covers Trulicity for type 2 diabetes with prior authorization (PA). The PA requirement means that a prescriber must document clinical justification before the state will reimburse the pharmacy claim.

Vermont's Department of Vermont Health Access (DVHA) administers the Medicaid pharmacy benefit and maintains a preferred drug list (PDL). GLP-1 receptor agonists are classified as non-preferred agents requiring PA on most state Medicaid formularies, and Vermont follows this pattern. To obtain PA approval, prescribers typically must demonstrate that the patient has tried and failed, or has a contraindication to, at least one preferred agent (often metformin, and sometimes a sulfonylurea or SGLT2 inhibitor) [3]. The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk, which can strengthen a PA request [4].

Processing time for Vermont Medicaid PA requests generally runs 24 to 72 hours. Denials can be appealed. Patients who qualify for both Medicare and Medicaid (dual-eligible beneficiaries) may have Trulicity covered under their Medicare Part D plan instead, with Medicaid acting as a secondary payer for any remaining cost-sharing.

How the Eli Lilly Savings Card Works in Vermont

Eli Lilly offers the Trulicity Savings Card for commercially insured patients. Eligible patients may pay as little as $25 per monthly prescription fill for up to 24 months. The card is not valid for patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs.

Vermont does not have state-specific restrictions that block manufacturer copay cards. Here is how to use the program: patients register online at Lilly's patient access portal, receive a digital or physical savings card with a BIN and PCN number, and present it to their pharmacist alongside their insurance card. The pharmacist processes the insurance claim first, then applies the savings card to the remaining copay. If the copay after insurance is $25 or less, the card provides no additional benefit. If the copay is higher, the card covers the difference up to the program's annual maximum (typically $150 per fill or a set annual cap).

One limitation: the savings card does not reduce the total cost of the drug to the insurer, so it does not count toward a patient's deductible on most high-deductible health plans. Patients in the deductible phase of their plan may still face significant out-of-pocket costs even with the card applied. Vermont residents on high-deductible plans paired with health savings accounts (HSAs) should confirm with their insurer whether copay card assistance counts toward their deductible accumulator.

Which Vermont Insurance Plans Cover Trulicity?

Most major commercial insurers operating in Vermont include Trulicity on their formularies, though tier placement and PA requirements vary by plan.

Blue Cross Blue Shield of Vermont (BCBSVT), the state's largest commercial insurer, typically places Trulicity on a specialty or non-preferred brand tier. MVP Health Care, which also operates in Vermont's exchange and employer markets, covers Trulicity with similar tiering. For both carriers, expect a PA requirement and a copay or coinsurance in the range of $50 to $150 per fill after deductible, depending on plan design. The REWIND trial (N=9,901), which demonstrated a 12% reduction in major adverse cardiovascular events (MACE) with dulaglutide 1.5 mg versus placebo over a median 5.4 years, strengthened the clinical case for insurer coverage of Trulicity in patients with cardiovascular risk factors [5].

Vermont Health Connect, the state's ACA marketplace, offers plans from BCBSVT and MVP. All marketplace plans must cover FDA-approved diabetes medications as part of the essential health benefits (EHB) package, though cost-sharing tiers differ by metal level. Bronze plans carry higher deductibles and copays; Silver plans with cost-sharing reductions offer the most favorable out-of-pocket terms for Trulicity.

Medicare Part D plans in Vermont also cover Trulicity, generally on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully implemented in 2025, limits total yearly drug costs for Medicare beneficiaries filling Trulicity [6].

Is Compounded Dulaglutide Legal in Vermont?

Yes. Compounded dulaglutide is available in Vermont through licensed 503A compounding pharmacies that hold valid state and federal registrations. These pharmacies may compound dulaglutide pursuant to a patient-specific prescription from a licensed prescriber.

Under federal law (the Drug Quality and Security Act of 2013), 503A pharmacies may compound copies of commercially available drugs when certain conditions are met, including a valid patient-specific prescription and compliance with USP compounding standards [7]. Vermont's Board of Pharmacy regulates 503A pharmacies operating within the state and requires adherence to USP <797> sterile compounding guidelines.

Pricing for compounded dulaglutide varies by pharmacy but can be substantially lower than brand-name Trulicity. Some 503A pharmacies advertise compounded GLP-1 receptor agonist formulations at a fraction of the branded cost. However, compounded products do not undergo FDA review for safety, efficacy, or bioequivalence. The FDA has issued multiple warnings about compounded semaglutide products containing salt forms (such as semaglutide sodium) that differ from the FDA-approved molecule, and similar concerns could apply to compounded dulaglutide [8].

Patients considering compounded dulaglutide should verify that the compounding pharmacy is licensed by the Vermont Board of Pharmacy, operates under a valid 503A registration, and follows current USP <797> standards. Prescribers should document the clinical rationale for using a compounded product.

Trulicity via Telehealth in Vermont

Vermont permits telehealth prescribing of Trulicity. State telehealth parity laws require insurers to cover telehealth visits at the same rate as in-person visits, which means a virtual consultation for Trulicity initiation or refill management is a covered benefit under most Vermont plans.

Vermont adopted permanent telehealth flexibilities following the COVID-19 public health emergency. The state allows audio-video telehealth for new and established patients, and prescribers licensed in Vermont may prescribe Trulicity after a telehealth evaluation without requiring an initial in-person visit [9]. This is relevant for patients in rural parts of the state, where the nearest endocrinologist may be over an hour away. Vermont's 2020 census showed that approximately 61% of the state's population lives in rural areas, making telehealth access a practical consideration for GLP-1 therapy management.

HealthRX and similar telehealth platforms can connect Vermont patients with licensed prescribers who evaluate candidacy for Trulicity, submit prior authorizations, and manage ongoing dose titration remotely. The standard titration schedule starts at 0.75 mg weekly for four weeks, then increases to 1.5 mg weekly, with optional further increases to 3.0 mg and 4.5 mg based on glycemic response and tolerability [2].

Trulicity Dose Options and Clinical Efficacy

Dulaglutide is available in four once-weekly doses: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. All doses are administered via a single-use, prefilled autoinjector pen. The cost per pen remains the same regardless of dose strength, so escalating from 0.75 mg to 4.5 mg does not increase the monthly price.

Clinical efficacy data supports dose-dependent glucose lowering. In the AWARD-11 trial (N=1,842), dulaglutide 3.0 mg reduced HbA1c by 1.71% and dulaglutide 4.5 mg reduced HbA1c by 1.87% from baseline at 36 weeks, compared to 1.54% with the 1.5 mg dose [10]. Weight loss also increased with higher doses: patients on 4.5 mg lost an average of 4.6 kg versus 3.0 kg on 1.5 mg at 36 weeks.

The REWIND trial provides the strongest cardiovascular evidence for dulaglutide. Over a median follow-up of 5.4 years, dulaglutide 1.5 mg reduced the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death by 12% compared to placebo (HR 0.88 to 95% CI 0.79-0.99, P=0.026) in patients with type 2 diabetes and cardiovascular risk factors [5]. Dr. Hertzel Gerstein, the REWIND principal investigator, stated: "These results show that dulaglutide has cardiovascular benefits in a broad population of people with type 2 diabetes, including those without prior cardiovascular disease."

The ADA's 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit (including dulaglutide) as preferred second-line therapy for patients with type 2 diabetes and established or high risk of ASCVD [4].

Strategies to Reduce Trulicity Cost in Vermont

Several approaches can lower out-of-pocket spending for Vermont patients.

Use the Eli Lilly savings card. Commercially insured patients should always apply the manufacturer savings card. At $25 per fill, this represents a savings of $100 to $300 or more per month compared to typical commercial copays.

Request a PA early. If your plan requires prior authorization, ask your prescriber to submit the PA before sending the prescription to the pharmacy. Failed PA submissions are the most common reason Vermont patients experience delays in starting Trulicity.

Compare pharmacy pricing. Cash prices can vary between Vermont pharmacies by $50 to $100, and mail-order pharmacies may offer lower pricing than retail locations. GoodRx, RxSaver, and similar discount aggregators can show real-time pricing at Vermont pharmacies.

Consider a 90-day fill. Many Vermont insurance plans offer lower per-unit pricing for 90-day supplies through preferred mail-order pharmacies. A 90-day fill at a reduced copay can save $20 to $60 over three separate 30-day fills.

Check Lilly's patient assistance program. Uninsured patients or those with household incomes below 400% of the federal poverty level may qualify for Lilly Cares, which provides Trulicity at no cost to eligible patients [11].

Explore compounded options with your prescriber. If cost remains prohibitive after exhausting insurance and manufacturer support, a compounded dulaglutide from a licensed Vermont 503A pharmacy may be an option. Discuss the tradeoffs (lower cost versus absence of FDA review) with your prescribing clinician.

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of type 2 diabetes noted that "cost and access barriers remain significant impediments to GLP-1 receptor agonist utilization, and clinicians should actively assist patients in identifying coverage pathways" [12].

Side Effects and Monitoring Considerations

The most common side effects of dulaglutide are gastrointestinal: nausea (12.4%), diarrhea (8.9%), vomiting (6.0%), and abdominal pain (6.5%) at the 1.5 mg dose in clinical trials [2]. These effects are typically transient and diminish over 4 to 8 weeks as patients titrate to their target dose.

Trulicity carries a boxed warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [2]. Vermont prescribers should document thyroid history before initiating therapy.

Monitoring during Trulicity treatment includes HbA1c every 3 months until stable, renal function at baseline and periodically (dulaglutide has renal dose considerations at eGFR <15 mL/min), and injection site reactions. Patients on concomitant insulin or sulfonylureas require monitoring for hypoglycemia, as the combination increases risk [2].